Beckman Coulter, a global leader in clinical diagnostics, today announced the commercial launch of its new DxH 690T haematology analyser. Designed to help laboratories streamline workflow and maximise uptime, the DxH 690T offers all the benefits of the company’s flagship DxH 900 haematology analyser to mid-size laboratories, including the recently released Early Sepsis Indicator
The DxH 690T analyser applies the company’s core haematology technologies – the enhanced Coulter Principle, VCS 360 and DataFusion – for high-resolution analysis of cells in their near-native states. This ensures medium-sized laboratories will achieve the right results the first time with no unnecessary reflex or repeats.
In addition, the DxH 690T offers the Early Sepsis Indicator, which is available to automatically report as part of a routine complete blood count (CBC) with white blood cell differential for adult patients in the emergency department.
Affecting approximately 30 million people globally every year, early recognition of sepsis can be challenging. Beckman Coulter’s Early Sepsis Indicator is the only haematology-based biomarker US Food and Drug Administration (FDA)-cleared specifically for augmenting the diagnosis of sepsis, so clinicians can know sooner and act faster.
